Tuberculosis-a World Health Organization Perspective

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2017 Feb 11

PMID 28185618

Citations 20

Authors

Giovanni Sotgiu

Giorgia Sulis

Alberto Matteelli

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is an important cause of morbidity and mortality worldwide. The World Health Organization (WHO) has implemented and scaled-up three important global public health strategies (i.e., DOTS, Stop TB, and End TB) to improve the international scenario. Their epidemiological impact was relevant, as they decreased the number of potential new cases of disease and death. However, the emergence and spread of TB/HIV coinfection and multidrug-resistant TB have hindered the progress towards the elimination of TB by 2050. More efforts are required to increase the global annual decline of the TB incidence rate. Political commitment is necessary, with global and national strategies oriented to the adoption and adaptation of the international, evidence-based recommendations on diagnosis, treatment, and prevention. Research and development activities should be planned to improve the current tools adopted to fight the disease. New rapid diagnostics, an updated and effective therapeutic armamentarium, and an effective preventive vaccine could represent the solution to address the current epidemiological threats.

Citing Articles

Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB.

Ahmad F, Ahmad S, Upadhyay T, Singh S, Khubaib M, Singh J Sci Rep. 2024; 14(1):16437.

PMID: 39013991 PMC: 11253001. DOI: 10.1038/s41598-024-66634-5.

Clinical manifestation and long-term follow-up of presumed ocular tuberculosis in China.

Xie J, Qu Y, Qian Z, Meng X, Lin J, Liu Y J Clin Tuberc Other Mycobact Dis. 2024; 34:100413.

PMID: 38259975 PMC: 10801207. DOI: 10.1016/j.jctube.2023.100413.

Prolonged survival of a patient with active MDR-TB HIV co-morbidity: insights from a strain with a unique genomic deletion.

Rubinstein M, Makhon A, Losev Y, Valenci G, Gatt Y, Margalit H Front Med (Lausanne). 2023; 10:1292665.

PMID: 38020140 PMC: 10657812. DOI: 10.3389/fmed.2023.1292665.

The Role of Ultrasound in the Diagnosis of Pulmonary Infection Caused by Intracellular, Fungal Pathogens and Mycobacteria: A Systematic Review.

Meli M, Spicuzza L, Comella M, La Spina M, Trobia G, Parisi G Diagnostics (Basel). 2023; 13(9).

PMID: 37175003 PMC: 10177819. DOI: 10.3390/diagnostics13091612.

Tuberculous Spondylodiscitis with Epidural Spread.

Alay H, Yilmaz Cankaya B Rev Soc Bras Med Trop. 2023; 56.

PMID: 36995788 PMC: 10042470. DOI: 10.1590/0037-8682-0617-2022.

References

Dye C, Williams B . Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A. 2000; 97(14):8180-5. PMC: 16690. DOI: 10.1073/pnas.140102797. View

Borgdorff M, Floyd K, Broekmans J . Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ. 2002; 80(3):217-27. PMC: 2567749. View

Dye C, Maher D, Weil D, Espinal M, Raviglione M . Targets for global tuberculosis control. Int J Tuberc Lung Dis. 2006; 10(4):460-2. View

DAmbrosio L, Dara M, Tadolini M, Centis R, Sotgiu G, van der Werf M . Tuberculosis elimination: theory and practice in Europe. Eur Respir J. 2014; 43(5):1410-20. DOI: 10.1183/09031936.00198813. View

Gupta R, Kim J, Espinal M, Caudron J, Pecoul B, Farmer P . Public health. Responding to market failures in tuberculosis control. Science. 2001; 293(5532):1049-51. DOI: 10.1126/science.1061861. View

Sotgiu G, Tiberi S, DAmbrosio L, Centis R, Zumla A, Migliori G . WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet. 2016; 387(10037):2486-7. DOI: 10.1016/S0140-6736(16)30729-2. View

Ma Z, Lienhardt C . Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009; 30(4):755-68, ix. DOI: 10.1016/j.ccm.2009.08.011. View

. Report on the meeting of the Second Ad Hoc Committee on the TB epidemic: recommendations to Stop TB Partners, Montreux, Switzerland, 18-19 September 2003. Int J Tuberc Lung Dis. 2004; 8(11):1279-84. View

Dye C, Garnett G, Sleeman K, Williams B . Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet. 1998; 352(9144):1886-91. DOI: 10.1016/s0140-6736(98)03199-7. View

10.

Chaisson R, Harrington M . How research can help control tuberculosis. Int J Tuberc Lung Dis. 2009; 13(5):558-68. View

11.

Sotgiu G, Tiberi S, DAmbrosio L, Centis R, Alffenaar J, Caminero J . Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Eur Respir J. 2016; 48(5):1503-1507. DOI: 10.1183/13993003.01249-2016. View

12.

Di Perri G, Cruciani M, Danzi M, Luzzati R, De Checchi G, Malena M . Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet. 1989; 2(8678-8679):1502-4. View

13.

Pontali E, Sotgiu G, DAmbrosio L, Centis R, Migliori G . Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016; 47(2):394-402. DOI: 10.1183/13993003.01891-2015. View

14.

Migliori G, Sotgiu G, Gandhi N, Falzon D, DeRiemer K, Centis R . Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2012; 42(1):169-179. PMC: 4498806. DOI: 10.1183/09031936.00136312. View

15.

Ross J, HORNE N, GRANT I, Crofton J . Hospital treatment of pulmonary tuberculosis; a follow-up study of patients admitted to Edinburgh hospitals in 1953. Br Med J. 1958; 1(5065):237-42. PMC: 2027011. DOI: 10.1136/bmj.1.5065.237. View

16.

Matiru R, Ryan T . The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management. Bull World Health Organ. 2007; 85(5):348-53. PMC: 2636664. DOI: 10.2471/blt.06.035402. View

17.

Russell S . The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg. 2004; 71(2 Suppl):147-55. View

18.

Kaufmann S, Hussey G, Lambert P . New vaccines for tuberculosis. Lancet. 2010; 375(9731):2110-9. DOI: 10.1016/S0140-6736(10)60393-5. View

19.

Espinal M, Kim S, Suarez P, Kam K, KHOMENKO A, Migliori G . Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283(19):2537-45. DOI: 10.1001/jama.283.19.2537. View

20.

Daley C, Small P, Schecter G, Schoolnik G, McAdam R, Jacobs Jr W . An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992; 326(4):231-5. DOI: 10.1056/NEJM199201233260404. View